Clinical Trial Update: Efficacy and Safety of CAZ-AVI in the Treatment of Infections Due to Carbapenem-resistant G- Pathogens in Chinese Adults [Phase 4]

View source ↗

Summary

Phase 4 trial results evaluate the efficacy and safety of ceftazidime-avibactam (CAZ-AVI) for carbapenem-resistant Gram-negative infections in Chinese adults, i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacteremia
• Hospital-acquired Pneumonia
• Intra-abdominal Infection
• Pyelonephritis
• Urinary Tract Infection
• Ventilator-associated Pneumonia

Drugs mentioned

• Ceftazidime-Avibactam (CAZ-AVI) (ceftazidime-avibactam)

Snippet

Sponsor: Pfizer | Conditions: Urinary Tract Infection, Acute Pyelonephritis | Phase 4 | Status: COMPLETED | Results posted: 2024-10-21